Received Mar 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | 5G422 | LA |
Redness was reported as worsened; she feels hot around the area; feels sore; This non-serious case was reported by a pharmacist via sales rep and described the occurrence of erythema in a 69-year-old female patient who received Herpes zoster (Shingles vaccine) (batch number 5G422, expiry date 07-JUL-2027) for erythema. Concurrent medical conditions included cough and infection. Concomitant products included benzonatate, prednisone and azithromycin. On 16-MAR-2026, the patient received the 1st dose of Shingles vaccine (left arm). In MAR-2026, an unknown time after receiving Shingles vaccine, the patient experienced skin warm (Verbatim: she feels hot around the area) and pain (Verbatim: feels sore). On 18-MAR-2026, the patient experienced erythema (Verbatim: Redness was reported as worsened). The outcome of the erythema was not resolved and the outcome of the skin warm and pain were not reported. The reporter considered the erythema to be related to Shingles vaccine. It was unknown if the reporter considered the skin warm and pain to be related to Shingles vaccine. The company considered the erythema to be related to Shingles vaccine. It was unknown if the company considered the skin warm and pain to be related to Shingles vaccine. Additional Information: GSK Receipt Date: 18-MAR-2026 Reporter reported no pain or itching.
Cough; Infection
BENZONATATE; PREDNISONE; AZITHROMYCIN